TIEFENBACHER
DEAD

Serial Number

79296462

Owner

Alfred E. Tiefenbacher GmbH & Co. KG

Attorney

Jennifer Fraser

Filing Date

Aug 26, 2020

Add to watchlist:

No watchlists yet
View on USPTO

TIEFENBACHER Trademark

Serial Number: 79296462

TIEFENBACHER is a trademark filed by Alfred E. Tiefenbacher GmbH & Co. KG on August 26, 2020. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Alfred E. Tiefenbacher GmbH & Co. KG (14 trademarks)

Van-der Smissen-Str. 1

Entity Type: 13

Trademark Details

Filing Date

August 26, 2020

Registration Date

Not Registered

Goods & Services

Medicinal specialities; generic medicines; pharmaceutical, chemical, biological and biochemical products, preparations and reagents, in particular for medical and diagnostic purposes; microorganisms, proteins, polypeptides, nucleotides, nucleic acids, cell-lines and cells, in particular for medical and diagnostic purposes, for investigation and characterisation of diseases, for medical research and development of medicines and for the manufacture of medicines and pharmaceuticals; sanitary preparations for medical purposes; dietetic preparations adapted for medical use; a full line of pharmaceuticals

Chemical, biological and biochemical products, preparations and reagents for scientific, research, laboratory and industrial purposes (other than for medical purposes); micro-organisms, proteins, polypeptides, nucleotides, nucleic acids, cell-lines and cells, in particular for scientific, research, laboratory and industrial purposes, other than for medical purposes; pharmaceutical, chemical, biological and biochemical products, preparations and reagents for researching and characterising diseases, for medical research and medicine development and for manufacturing medicines and pharmaceuticals; Chemical reagents for scientific use; biological diagnostic reagents for clinical or medical laboratory use; chemical preparations for general industrial manufacturing; Cells for scientific and research use; nucleic acid for laboratory use; biochemical, namely, polypeptides for in vitro research use; cultures of micro-organisms, other than for medical use; protein for industrial use, nucleotides for scientific and research use; Chemical additives for use in the manufacture of pharmaceuticals

Scientific and technological services, consultancy and research, in particular in the field of medicine, medical diagnostics, pharmacy, molecular biology, biotechnology, immunology and genetics, for medicine development and for manufacturing medicines and pharmaceuticals; scientific and industrial research and development, in particular in the fields of medicine, medical diagnostics, pharmacy, molecular biology, biotechnology, immunology and genetics, for development of medicines and for the manufacture of medicines and pharmaceuticals; investigation and development of medicines, diagnostic and analysis agents and therapy procedures (medical research); pharmaceutical, genealogical, bacteriological, biological, biochemical, chemical, molecular biological and forensic laboratories (other than medical consultancy); scientific experiments and providing scientific expertise in the fields of medicine, medical diagnostics, pharmacy, molecular biology, biotechnology, immunology and genetics, for development of medicines and for the manufacture of medicines and pharmaceuticals; providing of technical information relating to generic medicines; services in relation to and advice on product development and quality maintenance; services of a medical and veterinary laboratory, in particular testing of medicines for others, development of new medicines; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Technical consulting in the field of pharmaceutical studies; Consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; Pharmaceutical research services; pharmaceutical research and development; Technical research in the field of pharmaceutical studies; Research and development in the pharmaceutical and biotechnology fields; Testing, inspection, research, or development of pharmaceutical preparations for gene therapy; Development of pharmaceutical preparations and medicines; pharmaceutical products development; pharmaceutical drug development services; Medical and scientific research, namely, conducting clinical trials for others; Conducting research and clinical trials for others relating to medical devices and pharmaceuticals; conducting clinical trials for others; Consulting services for others in the field of design, planning, and implementation project management of scientific research and clinical trials; Providing medical and scientific research information in the fields of pharmaceuticals and clinical trials; design and testing for new product development; chemical laboratories; Scientific and technological services, namely, scientific research, analysis, testing in the fields of pharmaceutical and drug development; scientific investigations for medical purposes; quality control for others; pharmaceutical drug development services; consultation in the private label manufacture and custom manufacture of pharmaceuticals and drugs

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Apr 24, 2023 FINT
FINAL DISPOSITION NOTICE SENT TO IB
Mar 31, 2023 FICS
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Mar 31, 2023 FICR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Apr 10, 2022 OPNX
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Mar 31, 2022 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Mar 31, 2022 ABN2
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 23, 2022 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Mar 23, 2022 OPNR
NOTIFICATION OF FINAL REFUSAL EMAILED
Sep 17, 2021 GNFN
FINAL REFUSAL E-MAILED
Sep 17, 2021 GNFR
FINAL REFUSAL WRITTEN
Sep 17, 2021 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 27, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 26, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 26, 2021 TROA
NEW REPRESENTATIVE AT IB RECEIVED
Jun 5, 2021 NREP
REFUSAL PROCESSED BY IB
Feb 14, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 25, 2021 RFCS
REFUSAL PROCESSED BY MPU
Jan 25, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jan 6, 2021 RFCR
NON-FINAL ACTION WRITTEN
Jan 5, 2021 CNRT
ASSIGNED TO EXAMINER
Dec 27, 2020 DOCK
APPLICATION FILING RECEIPT MAILED
Oct 30, 2020 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 26, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 22, 2020 REPR